ApoB versus non-HDL-cholesterol: Diagnosis and cardiovascular risk management

References

• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502
   PubMed Web of Science ®Google Scholar
• Ketelhuth DFJ, Rios FJO, Wang Y, et al. Identification of a danger-associated peptide from apolipoprotein B100 (ApoBDS-1) that triggers innate proatherogenic responses. Circulation 2011;124:2433–43
   Google Scholar
• Avraham-Davidi I, Ely Y, Pham VN, et al. ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1. Nat Med 2012;18:967–73
   Google Scholar
• Young SG. Recent progress in understanding apolipoprotein B. Circulation 1990;82:1574–94
   PubMed Web of Science ®Google Scholar
• Stalenhoef AF, Malloy MJ, Kane JP, Havel RJ. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans. Proc Natl Acad Sci 1984;81:1839–43
   Google Scholar
• Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis 1991;89:109–16
   Web of Science ®Google Scholar
• Sniderman A, Tremblay A, Bergeron J, et al. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. J Clin Lipidol 2007;1:256–63
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Tremblay A, De Graaf J, Couture P. Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein. J Clin Lipidol 2012;6:427–33
   Google Scholar
• Sniderman AD, St-Pierre AC, Cantin B, et al. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003;91:1173–7
   PubMed Web of Science ®Google Scholar
• Contois JH, McConnell JP, Sethi AA, et al; AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009;55:407–1
   PubMed Web of Science ®Google Scholar
• AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2013;59:752–70
   Google Scholar
• Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337–45
   PubMed Web of Science ®Google Scholar
• The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000
   PubMed Web of Science ®Google Scholar
• The Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;20;307:2499–506
   Google Scholar
• Sniderman AD Furberg CD. Cardiovascular disease risk prediction factors. JAMA 2012;308:1969
   Google Scholar
• Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study – implications for LDL management. J Clin Lipidol 2007;1:583–92
   PubMed Web of Science ®Google Scholar
• Otvos JD, Mora S, Shalaurova I, et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 2011;5:105–13
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis 2012;225:444–9
   PubMed Web of Science ®Google Scholar
• Sniderman A, McQueen M, Contois J, et al. Why is non−high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?. J Clin Lipidol 2010;4:152–5
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Catapano AL, Reiner Ž, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217:1–44 (and in Eur Heart J. 2011 Jul;32(14):1769-818)
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Grégoire J, Hegele RA, et al. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol 2013;29:151–67
   PubMed Web of Science ®Google Scholar
• Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012;5:2–5
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists' (CTT) Collaboration. Cholesterol treatment trialists collaboration efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376:1670–81
   Google Scholar
• Takagi H, Umemoto T. Limit to benefits of large reductions in low-density lipoprotein cholesterol levels: use of fractional polynomials to assess the effect of low-density lipoprotein cholesterol level reduction in metaregression of large statin randomized trials. JAMA Intern Med 2013;173:1028–9
   PubMed Web of Science ®Google Scholar
• Boekholdt S, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein b levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:1302–9
   PubMed Web of Science ®Google Scholar
• Parish S, Offer A, Clarke R, et al; Heart Protection Study Collaborative Group. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012;125:2469–78
   PubMed Web of Science ®Google Scholar
• Sniderman A, Thanassoulis G, Couture P, et al. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering. J Clin Lipidol 2012;6:303–9
   PubMed Web of Science ®Google Scholar
• Sniderman AD, De Graaf J, Couture P. Low-density lipoprotein-lowering strategies: target versus maximalist versus population percentile. Curr Opin Cardiol 2012;27:405–11
   Google Scholar
• Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins – an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:34–44
   PubMed Web of Science ®Google Scholar
• Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol 2010;6:335–46
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Albers JJ, Chait A, et al. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147–55
   PubMed Web of Science ®Google Scholar
• Veerkamp MJ, de Graaf J, Hendriks JC, et al. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 2004;109:2980–5
   PubMed Web of Science ®Google Scholar
• Mahley RW, Huang Y, Rall SC. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J Lipid Res 1999;40:1933–49
   PubMed Web of Science ®Google Scholar
• Fredrickson DS, Morganroth J, Levy RI. Type III hyperlipoproteinemia: an analysis of two contemporary definitions. Ann Intern Med 1975;82:150–7
   PubMed Web of Science ®Google Scholar
• Zambon A, Brunzell JD, Torres A, et al. Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolaemia and lipoprotein lipase deficiency. Lancet 1993;341:1119–21
   Google Scholar
• Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013;381:1293–301
   PubMed Web of Science ®Google Scholar